Gena Wang
Stock Analyst at Barclays
(3.12)
# 1,141
Out of 5,165 analysts
237
Total ratings
43.67%
Success rate
0.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $19.10 | +318.85% | 8 | Feb 4, 2026 | |
| CYTK Cytokinetics | Assumes: Overweight | $87 | $60.83 | +43.02% | 6 | Jan 28, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $21.82 | +129.15% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $8.48 | +289.15% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $53.31 | -53.10% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $13.38 | +4.63% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.36 | +177.32% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $66.75 | +1.87% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $16.66 | +20.05% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $466.10 | -11.18% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $7.48 | +20.32% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $9.30 | -3.23% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $318.91 | +65.25% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $72.31 | +31.38% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $57.43 | +39.30% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.46 | +131.21% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $23.31 | -27.07% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $8.79 | +320.93% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $48.42 | +15.65% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $25.49 | -17.61% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $9.68 | +220.41% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.54 | +18.11% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $23.62 | -61.90% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $6.63 | +277.07% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.69 | +134.07% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $6.07 | +48.27% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $4.95 | +5,455.56% | 1 | Jan 6, 2017 |
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $19.10
Upside: +318.85%
Cytokinetics
Jan 28, 2026
Assumes: Overweight
Price Target: $87
Current: $60.83
Upside: +43.02%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $21.82
Upside: +129.15%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $8.48
Upside: +289.15%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $53.31
Upside: -53.10%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $13.38
Upside: +4.63%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.36
Upside: +177.32%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $66.75
Upside: +1.87%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $16.66
Upside: +20.05%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $466.10
Upside: -11.18%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $7.48
Upside: +20.32%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $9.30
Upside: -3.23%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $318.91
Upside: +65.25%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $72.31
Upside: +31.38%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $57.43
Upside: +39.30%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.46
Upside: +131.21%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $23.31
Upside: -27.07%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $8.79
Upside: +320.93%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $48.42
Upside: +15.65%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $25.49
Upside: -17.61%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $9.68
Upside: +220.41%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.54
Upside: +18.11%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $23.62
Upside: -61.90%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $6.63
Upside: +277.07%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.69
Upside: +134.07%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $6.07
Upside: +48.27%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $4.95
Upside: +5,455.56%